Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Over half of refractory AML patients responded to combo

Advani A et al. ASH 2017, Abstract 150.

Key clinical point: MEC plus ixazomib is well tolerated and effective in relapsed/refractory AML.

Major finding: The overall response rate was 53%.

Study details: A phase 1 trial involving 30 patients.

Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.

Source: Advani A et al. ASH 2017, Abstract 150.

Read the full article.

Citation:

Advani A et al. ASH 2017, Abstract 150.

This Week's Must Reads

Screening for Syphilis Infection in Pregnant Women, JAMA; 2018 Sep 4; US Preventive Services Task Force

Treatment Intensification Guidelines for T2D , Ann Intern Med; ePub 2018 Sep 4; Roglic, et al

Immediate vs Gradual Nicotine Reduction in Cigarettes, JAMA; ePub 2018 Sep 4; Hatsukami, et al

Prevalence of Diabetes Among US Adults, BMJ; ePub 2018 Aug 27; Xu, Liu, et al

Effect of Fish Oil Supplementation in Pregnancy, BMJ; ePub 2018 Sep 4; Vinding, Stokholm, et al

Must Reads in Oncology

Trends in HPV-Associated Cancers in the US, MMWR; 2018 Aug 24; Van Dyne, Henley, et al

Screening for Cervical Cancer in Primary Care, JAMA; 2018 Aug 21; Kim, Burger, et al

Endometrial Ca Risk with Postmenopausal Bleeding, JAMA Intern Med; ePub 2018 Aug 6; Clarke, et al

Can Mailed FIT Outreach Increase CRC Screening?, JAMA Intern Med; ePub 2018 Aug 6; Coronado, et al

Mortality Due to Cirrhosis & Liver Cancer in the US, BMJ; ePub 2018 Jul 18; Tapper, Parikh